Limbic AI

About Limbic AI

Limbic AI is a London-based company founded in 2017 by Dr. Ross Harper (CEO) and Sebastiaan de Vries (CTO) to address the supply-demand imbalance in mental healthcare. Dr. Harper's background is in neuroscience and psychiatry, while de Vries is the ex-founder of a successful Dutch payment app. The company develops clinical-grade artificial intelligence tools designed to augment the capabilities of mental health professionals, improve operational efficiency, and expand patient access to care.

Limbic's core business revolves around providing a suite of AI-powered software solutions to healthcare organizations, primarily in the public sector like the UK's National Health Service (NHS), as well as to US health systems and payers. The company operates on a Software-as-a-Service (SaaS) model, integrating its tools into existing clinical workflows and electronic health records (EHR). Its products are co-designed with NHS Mental Health Services to ensure they meet the needs of both clinicians and patients.

The company's main product is Limbic Access, an AI-powered conversational chatbot that functions as a digital front door for mental health services. This tool automates patient intake and triage, guiding users through self-referral with an interactive and empathetic interface. It collects patient data, screens for various conditions, predicts diagnoses with high accuracy, and flags high-risk cases for prioritization by clinicians. This streamlines the administrative burden on therapists, reducing assessment times and waiting lists. Another key product is Limbic Care, a generative AI companion app that provides on-demand support to patients between therapy sessions. It delivers personalized Cognitive Behavioral Therapy (CBT) exercises and activities based on the patient's specific treatment plan created by their clinician.

A significant differentiator for Limbic is its regulatory standing. Its AI therapy assistant is the first of its kind to receive Class IIa UKCA medical device certification, which verifies its clinical effectiveness, safety, and risk management processes. The proprietary AI architecture, called the "Limbic Layer," sits between the user and a large language model to ensure all interactions are based on validated clinical guidance. The company has demonstrated considerable success within the NHS, where it has been used by a significant portion of Talking Therapies services, supporting hundreds of thousands of patients. Studies have shown that the use of Limbic's chatbot increases referral rates, particularly among minority and underserved groups, and improves patient recovery rates.

In March 2024, Limbic announced a $14 million Series A funding round led by Khosla Ventures to fuel its expansion into the U.S. market.